Migraine: advances in treatment
Abstract
Increased understanding of the pathophysiology of migraine has resulted in the development of therapies targeting calcitonin gene-related peptide and its receptor. Ditans, which are serotonin 5HT 1F receptor agonists, have demonstrated efficacy in acute management and bypass vascular risks associated with triptans, which are 5HT 1B/1D receptor agonists. However, despite favourable safety and efficacy data, many patients do not respond to these therapies. Treatments targeting pituitary adenylate cyclase activating polypeptide and other potential targets, including amylin and adrenomedullin and their receptors, K ATP and transient receptor potential ion channels, as well as neuronal nitric oxide synthase, are emerging. Improving our understanding of patient heterogeneity in migraine biology may pave the way for precision medicine in migraine management.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.